Q&A: Pfizer's Dx Division Head Discusses Pharma Giant's Focus on Personalized Medicine
September 09, 2009
Q&A: Pfizer's Dx Division Head Discusses Pharma Giant's Focus on Personalized Medicine
In an interview with Pharmacogenomics Reporter this week, Hakan Sakul provided a snapshot of Pfizer's efforts in personalized medicine, the company's stance on regulatory issues, and its overall focus on "omics"-guided medicine.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Pfizer, Abbott Ink Deal to Develop Companion Dx for PGx-based NSCLC Drug
September 2, 2009 / Pharmacogenomics Reporter - UK Startup DNA Electronics Developing Handheld Device to Detect Genetic Risk for Drug AEs
February 25, 2009 / Pharmacogenomics Reporter - MDx/CDx Focus: Siemens Inks Companion Dx Partnerships; FDA Accepts Roche's Pertuzumab BLA
February 8, 2012 / Pharmacogenomics Reporter - Biodesix Inks Deal to Test Veristrat in Phase III Clinical Trial for Kadmon Lung Cancer Drug
March 2, 2012 / ProteoMonitor - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter